Serotonergic and Adrenergic Drug Interactions Associated with Linezolid: A Critical Review and Practical Management Approach

Ramsey, Tasha D; Lau, Tim T Y; Ensom, Mary H H

doi:10.1345/aph.1r604

Cited by 47 publications

(26 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, linezolid therapy has been reported to be associated with myelosuppression, peripheral and optic neuropathy, and lactic acidosis especially with prolonged use [ 35 ]. Further, linezolid-associated serotonergic and adrenergic drug interactions can lead to severe AEs such as hypertensive episodes [ 36 ]. The rates of AEs reported for daptomycin in this retrospective observational study were low, although these may not be compared to AE reporting in a controlled clinical trial [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry

Gonzalez-Ruiz

Gargalianos-Kakolyris

Timerman³

et al. 2015

Adv Ther

View full text Add to dashboard Cite

IntroductionThe aim of this study was to evaluate the clinical outcomes and safety of daptomycin therapy in patients with serious Gram-positive infections.MethodsPatients were enrolled in the European Cubicin® Outcomes Registry and Experience (EU-CORESM), a non-interventional, multicenter, observational registry. The real-world data were collected across 18 countries (Europe, Latin America, and Asia) for patients who had received at least one dose of daptomycin between January 2006 and April 2012. Two-year follow-up data were collected until 2014 for patients with endocarditis, intracardiac/intravascular device infection, osteomyelitis, or orthopedic device infection.ResultsA total of 6075 patients were enrolled. The most common primary infections were complicated skin and soft tissue infection (31.7%) and bacteremia (20.7%). Staphylococcus aureus was the most frequently reported pathogen (42.9%; methicillin-resistant S. aureus [MRSA], 23.2%), followed by Staphylococcus epidermidis and other coagulase-negative staphylococci (CoNS, 28.5%). The most commonly prescribed dose of daptomycin was 6 mg/kg/day (43.6%), and the median duration of therapy was 11 (range 1–300) days. Overall clinical success rate was 80.5%, and was similar whether daptomycin was used as first-line (82.9%) or second-line (79.2%) therapy. Clinical success rates were high in patients with S.aureus (83.9%; MRSA 83.0%) and CoNS (including S. epidermidis, 82.5%) infections. The majority of patients with endocarditis or intracardiac/intravascular device infection (86.7%) or osteomyelitis/orthopedic device infection (85.9%) had a sustained response during the 2-year follow-up period. There were no new or unexpected safety findings.ConclusionResults from real-world clinical experience showed that daptomycin is a valuable therapeutic option in the management of various difficult-to-treat Gram-positive infections.FundingThis study was funded by Novartis Pharma AG.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0220-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry

Gonzalez-Ruiz

Gargalianos-Kakolyris

Timerman³

et al. 2015

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Most antidepressants take two to eight weeks to demonstrate antidepressant effects, although a placebo effect may be seen prior to this [ 15 , 16 ]. Despite the knowledge that the antidepressant effect will occur at some point, even post-ICU discharge, clinicians may still have reluctance to initiate these drugs in an ICU setting due to side effects like cardiac conduction disturbances, sedative effects, risk of serotonin syndrome, especially with concomitant linezolid antibiotic [ 17 ], potential for increased bleeding [ 18 , 19 ], and other side effects such as dry mouth and blurred vision. Indeed, this intervention did not demonstrate a substantial change in the prevalence of post-ICU depression in our study based on historical cohorts; thus these risks may outweigh any potential benefits of antidepressant initiation in the ICU.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective, Pilot Study of De Novo Antidepressant Medication Initiation in Intensive Care Unit Patients and Post-ICU Depression

Haines

Hild

et al. 2017

Critical Care Research and Practice

View full text Add to dashboard Cite

Post-ICU Syndromes (PICS) remain a devastating problem for intensive care unit (ICU) survivors. It is currently unknown if de novo initiation of an antidepressant medication during ICU stay decreases the prevalence of post-ICU depression. We performed a retrospective, pilot study evaluating patients who had not previously been on an antidepressant medication and who were started on an antidepressant while in the trauma surgical, cardiothoracic, or medical intensive care unit (ICU). The PHQ-2 depression scale was used to ascertain the presence of depression after ICU discharge and compared this to historical controls. Of 2,988 patients admitted to the ICU, 69 patients had de novo initiation of an antidepressant medication and 27 patients were alive and available for study inclusion. We found the prevalence of depression in these patients to be 26%, which is not statistically different than the prevalence of post-ICU depression in historical controls [95% CI (27.6%, 51.6%)]. De novo initiation of an antidepressant medication did not substantially decrease the prevalence of post-ICU depression in this retrospective, pilot study.

show abstract

“…Currently, nonselective, irreversible MAO A/B blockers (phenelzine and tranylcypromine) are very rarely used in clinical psychiatry. However, some clinically used drugs (e.g., the antibiotic linezolid) are mild nonselective MAO blockers and thus they can also evoke this reaction, known as the “cheese effect.” This risk is nonetheless low …”

Section: Drugs With Possible Toxic Effects On Both Cardiomyocytes Andmentioning

confidence: 99%

Comprehensive review of cardiovascular toxicity of drugs and related agents

Mladěnka

Applová

Patočka

et al. 2018

Medicinal Research Reviews

215

120

View full text Add to dashboard Cite

Cardiovascular diseases are a leading cause of morbidity and mortality in most developed countries of the world. Pharmaceuticals, illicit drugs, and toxins can significantly contribute to the overall cardiovascular burden and thus deserve attention. The present article is a systematic overview of drugs that may induce distinct cardiovascular toxicity. The compounds are classified into agents that have significant effects on the heart, blood vessels, or both. The mechanism(s) of toxic action are discussed and treatment modalities are briefly mentioned in relevant cases. Due to the large number of clinically relevant compounds discussed, this article could be of interest to a broad audience including pharmacologists and toxicologists, pharmacists, physicians, and medicinal chemists. Particular emphasis is given to clinically relevant topics including the cardiovascular toxicity of illicit sympathomimetic drugs (e.g., cocaine, amphetamines, cathinones), drugs that prolong the QT interval, antidysrhythmic drugs, digoxin and other cardioactive steroids, beta‐blockers, calcium channel blockers, female hormones, nonsteroidal anti‐inflammatory, and anticancer compounds encompassing anthracyclines and novel targeted therapy interfering with the HER2 or the vascular endothelial growth factor pathway.

show abstract

Serotonergic and Adrenergic Drug Interactions Associated with Linezolid: A Critical Review and Practical Management Approach

Cited by 47 publications

References 40 publications

Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry

Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry

A Retrospective, Pilot Study of De Novo Antidepressant Medication Initiation in Intensive Care Unit Patients and Post-ICU Depression

Comprehensive review of cardiovascular toxicity of drugs and related agents

Contact Info

Product

Resources

About